Literature DB >> 3668010

Frequency, levels, and significance of blood eosinophilia in systemic sclerosis, localized scleroderma, and eosinophilic fasciitis.

V Falanga1, T A Medsger.   

Abstract

Blood eosinophilia is a common feature of eosinophilic fasciitis and is variably reported in systemic sclerosis and localized scleroderma. Since these diseases share cutaneous fibrosis as the final outcome and have other clinical and pathologic features that are difficult to differentiate, the presence of blood eosinophilia may be a further source of confusion. In this study, we examined the frequency and level of blood eosinophilia in 715 patients with systemic sclerosis, 72 patients with localized scleroderma, and 22 patients with clinically active eosinophilic fasciitis. When defined as greater than 400 cells/mm3, eosinophilia was present in 7% of patients with systemic sclerosis, 31% of patients with localized scleroderma, and 83% of patients with eosinophilic fasciitis. Greater than 1000 eosinophils/mm3 were present less frequently in systemic sclerosis (1%) and localized scleroderma (8%) than in eosinophilic fasciitis (61%). No difference in the frequency of eosinophilia was present in patients with the limited cutaneous CREST syndrome or the diffuse cutaneous variety of systemic sclerosis, and in these patients the presence of eosinophilia did not correlate with the extent of cutaneous or internal organ involvement or with other laboratory abnormalities. Among patients with localized scleroderma, eosinophilia was more common in those with linear scleroderma and generalized morphea than in those with morphea, and both the frequency and level of eosinophilia were greater in individuals with clinically active disease (p less than 0.02). Eosinophilia was a persistent feature in untreated patients with active eosinophilic fasciitis, even up to 30 months of disease duration.

Entities:  

Mesh:

Year:  1987        PMID: 3668010     DOI: 10.1016/s0190-9622(87)70251-5

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  14 in total

1.  Unusual presentation of eosinophilic fasciitis (EF) with a raised ALT.

Authors:  Thomas Batty; Shuja Majeed; Christina Wlodek; Harsha Gunawardena
Journal:  BMJ Case Rep       Date:  2018-12-22

2.  An unusual case of eosinophilia, myalgia and skin contractures: Shulman's disease revisited.

Authors:  R K Anadure; S Shankar; Aneesh Mohimen; Arpitha Pemmaraju; Jitumani Kalita
Journal:  Med J Armed Forces India       Date:  2020-03-12

3.  Eosinophilic fasciitis presenting with a reactive hepatitis.

Authors:  A E Loeliger; H R van den Brink; R H Derksen; J W Bijlsma
Journal:  Clin Rheumatol       Date:  1991-12       Impact factor: 2.980

Review 4.  Clinical aspects of systemic sclerosis (scleroderma).

Authors:  R M Silver
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

Review 5.  Rheumatologic disease with peripheral eosinophilia.

Authors:  Nüket Bavbek; Ayşe Kargili; Handan Cipil; Ali Koşar; Yaşar Karaaslan
Journal:  Rheumatol Int       Date:  2004-04-20       Impact factor: 2.631

6.  Atypical Presentation of Eosinophilic Fasciitis with Pitting Edema.

Authors:  Chih-Wei Chang; Matthew S Lau
Journal:  Hawaii J Med Public Health       Date:  2015-09

Review 7.  Eosinophilia in rheumatologic diseases: a prospective study of 1000 cases.

Authors:  Ayşe Kargili; Nüket Bavbek; Arif Kaya; Ali Koşar; Yaşar Karaaslan
Journal:  Rheumatol Int       Date:  2004-04-06       Impact factor: 2.631

Review 8.  Evaluation and differential diagnosis of marked, persistent eosinophilia.

Authors:  Thomas B Nutman
Journal:  Immunol Allergy Clin North Am       Date:  2007-08       Impact factor: 3.479

Review 9.  Use of H-1 Antihistamine in Dermatology: More than Itch and Urticaria Control: A Systematic Review.

Authors:  Chang-Yu Hsieh; Tsen-Fang Tsai
Journal:  Dermatol Ther (Heidelb)       Date:  2021-04-12

Review 10.  Eosinophilic fasciitis: report of two cases and a systematic review of the literature dealing with clinical variables that predict outcome.

Authors:  Yukie Endo; Atsushi Tamura; Youichiro Matsushima; Tomoko Iwasaki; Michiko Hasegawa; Yayoi Nagai; Osamu Ishikawa
Journal:  Clin Rheumatol       Date:  2007-03-08       Impact factor: 3.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.